Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Viatris (VTRS) stock in plain English

Free brief · no signupStart here
VTRSPublished Nov 16, 2026
Viatris Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells generic medications, biosimilars, and legacy branded prescription drugs across retail pharmacies and hospital networks worldwide.
Assets:
Manufacturing networkOperates approximately 40 manufacturing facilities across the globe
Product portfolioSupplies roughly 1,400 approved drug molecules across major therapeutic areas
Global workforceEmploys approximately 38,000 people across commercial and production sites
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

42
OPS ScoreOperating finances
Latest quote
-1.97%$19.88
$22.79B
n/a (loss)
$14.70B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was VTRS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Viatris (VTRS) do?

Viatris Inc (VTRS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells generic medications, biosimilars, and legacy branded prescription drugs across retail pharmacies and hospital networks worldwide. Manufactures and distributes off-patent brand-name medications and generic prescription drugs globally. It is worth $22.79B on the market and sold $14.70B over the last year.

Market cap
$22.79B
P/E ratio
None (reported a loss)
Annual sales
$14.70B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 16, 2026

Brands and businesses behind VTRS

  • Lipitor: Sells cholesterol-lowering medication in established markets through pharmacies and healthcare providers.
  • Norvasc: Generates revenue selling prescription blood pressure medications across global hospital and pharmacy channels.
  • Lyrica: Earns revenue from sales of prescription nerve pain and fibromyalgia capsules worldwide.
  • EpiPen: Sells emergency epinephrine auto-injectors to patients through pharmacy chains and distributors.
  • Viagra: Generates revenue through sales of branded sildenafil for erectile dysfunction in international markets.
  • Celebrex: Sells nonsteroidal anti-inflammatory prescription medication for arthritis pain management globally.

VTRS’s flags, in plain English

Each flag is a number from Viatris’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Cheap on Cash Flow

Priced at 10.8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Wide Gross Margin

Gross margin of 40.8% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -4.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about VTRS

How big is Viatris?

Viatris’ market cap is $22.79B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $14.70B: what customers paid the company over the last year, before any costs.

What is VTRS’s P/E ratio?

VTRS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with VTRS?

Generic drug price deflation across core markets continuously compresses profit margins on legacy medicines. That is one risk on Viatris’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Viatris’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. VTRS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card